×

Syahriel Abdullah, Researcher / Lecturer, Institute for Tropical Biology and Conservation, Universiti Malaysia Sabah

Dr. Syahriel Abdullah is a Senior Lecturer at the Institute for Tropical Biology and Conservation (ITBC), Universiti Malaysia Sabah (UMS), where he leads strategic research initiatives at the intersection of tropical biodiversity and advanced drug development. Based in Borneo, a global biodiversity ...

Close Full biography

Syahriel Abdullah, Researcher / Lecturer, Institute for Tropical Biology and Conservation, Universiti Malaysia Sabah

Josephine Alba, Senior expert I data science, Novartis

×

Khalid Al-Kinani, Professor and Dept. Chair, University of Baghdad

Khalid Al-Kinani is a distinguished Professor and Department Chair at the University of Baghdad, renowned for his expertise in the field of biologics. He also serves as a mamber of the 2nd Medicines Reguistration Committee at the Iraqi Ministry of Health (MOH) and a former Head of Biologics and...

Close Full biography

Khalid Al-Kinani, Professor and Dept. Chair, University of Baghdad

Joerg Altekrueger, Director Drug Substance Development Switzerland, Novartis Pharma AG

×

Antonio Angelastro, Senior Scientist, AstraZeneca

Antonio is a Senior Scientist in AstraZeneca’s Biologics Engineering—Protein Engineering and New Modalities division, specialising in pre-clinical biopharmaceutical development. His expertise lies in bioconjugation chemistry and the design of advanced protein conjugates, helping to shape innovative ...

Close Full biography

Antonio Angelastro, Senior Scientist, AstraZeneca

Marcelino Arciniega Castro, Head of Structural Biology and Data Analysis, JJP Biologics

×

Philip Arlen, President And Chief Executive Officer, Precision Biologics Inc

Philip M. Arlen, M.D., President and Chief Executive Officer: Dr. Arlen spent 11 years at the National Cancer Institute, USA, most recently as the Director of the Clinical Research Group for the Laboratory of Tumor Immunology and Oncology. At the NCI, Dr. Arlen focused on the development of a...

Close Full biography

Philip Arlen, President And Chief Executive Officer, Precision Biologics Inc

×

Baptiste Balbuena, Application Engineer Downstream, Merck Group

Baptiste Balbuena is a Biomanufacturing Engineer MSAT EMEA passioned by bioprocessing. Holder of a master’s degree in project management and biotechnologies innovation from Montpellier University, he dedicated last years to technically support customers with various problematics concerning...

Close Full biography

Baptiste Balbuena, Application Engineer Downstream, Merck Group

Abhishek Bansod, Senior Safety Scientist, Roche

×

Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre

Dr Alain Beck is Senior Director, Biologics CMC and Developability (Institut de Recherche Pierre Fabre, France), co-founder and Associate Editor of mAbs journal (2009) and chairman of MabDesign SAB (2014). He is or was involved in +12 clinical stage biologics R&D programs including dalotuzumab/ ...

Close Full biography

Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre

Jason Beckwith, SVP Talent Science & Thought Leadership | BioTalent, Evolution

×

Julia Behnke, CEO and Co-Founder, ingineeon | advanced immunotherapeutics

Julia has been researching on immune proteins already during her PhD at a leading hospital in the US. Afterwards Julia was involved in development of various therapeutics from preclinics up to clinical and market access strategy development in the industry. After combining this expertise with...

Close Full biography

Julia Behnke, CEO and Co-Founder, ingineeon | advanced immunotherapeutics

×

Nicola Beltraminelli, Chief Development Officer, Head of RED, INNATE PHARMA

Dr. Nicola Beltraminelli joined Innate Pharma as Vice President and Chief Development Officer in January 2022 and was recently appointed as Head of Reasearch Early Development of the organization. Dr. Beltraminelli brings 25 years of biotech experience to the role, and specifically in the...

Close Full biography

Nicola Beltraminelli, Chief Development Officer, Head of RED, INNATE PHARMA

×

Tobias Bergauer, Senior Principal Scientist, Roche Pharma

20+ years of experience in R&D, project, and portfolio management in the biotech and pharmaceutical industry, with a focus on genetic and genomic biomarkers, associated assay technologies, and genomic therapeutic modalities. My core competencies include research project, portfolio...

Close Full biography

Tobias Bergauer, Senior Principal Scientist, Roche Pharma

Matthieu Besneux, Principal Scientist, Head of In Vitro Pharmacology, Ennovate

Vladimir Bobkov, Principal Scientist, Argenx

×

Sara Bonetti, Senior Scientist, Salipro Biotech AB

Sara Bonetti is Senior Scientist at Salipro Biotech, a company located in Stockholm, Sweden, working on stabilizing challenging drug targets for drug discovery. Prior to joining Salipro Biotech, Sara obtained her PhD in Biochemistry and Molecular Biology from the University of...

Close Full biography

Sara Bonetti, Senior Scientist, Salipro Biotech AB

Louis Boon, Chief Scientific Officer and Board member JJP Biologics, JJP Biologics

Laure Bouchez, Executive in Residence and CSO Ennovate, General Inception

×

Frederic Bouder, Professor Of Risk Management, University of Stavanger

Prof. Frederic Bouder has developed policy-oriented research on risk communication and risk regulation, with a strong transatlantic and comparative dimension. His interest for medicines has taken central stage in his career including in the area of vaccines and biotechnology. His research interests ...

Close Full biography

Frederic Bouder, Professor Of Risk Management, University of Stavanger

×

Diego Braguglia, GP, Vi Partners

Diego has more than two decades of venture capital experience and has developed a solid experience in creating, growing and exiting ventures in therapeutics and medical devices. He served as chairman and non-executive director in Endoart (acquired by Allergan), Endosense (acquired by St...

Close Full biography

Diego Braguglia, GP, Vi Partners

Sebastian Breuer, Innovation Lead & Preclinical Project Leader at pRED, Roche Diagnostics GmbH

Bryan Briney, Associate Professor, Scripps Research

Sascha Oliver Bucher, Co-Founder and Partner, Forty51 Ventures AG

×

Luigi Buonaguro, MD, Innovative Immunological Models Unit, National Cancer Institute

Dr. Luigi Buonaguro is the Director of the Innovative Immunological Models at the National Cancer Institute - IRCCS “Pascale ”, Naples – Italy. He is an expert in identification and characterization of tumor antigens for preventive/therapeutic cancer vaccine development. His focus is mostly on...

Close Full biography

Luigi Buonaguro, MD, Innovative Immunological Models Unit, National Cancer Institute

Floris Burgering, Global Manufacturing Network Program and Risk manager, Genentech/Roche

×

Johannes Buyel, Head of Department, B.O.K.U.

After a B.Sc. in Biotechnology at the RWTH Aachen University (2006), Johannes studied in Sweden and the USA during his masters, which he finished with honors in 2009. He finished his first PhD focusing on recombinant protein expression in plants in 2013, then starting as a group leader for...

Close Full biography

Johannes Buyel, Head of Department, B.O.K.U.

Marta Carrasco, Data Governance & Operations Lead, Roche

Prasun Chakraborty, Founder & CEO, Genevation LTD

×

Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute

A/Prof Andre Choo obtained his PhD from the University of Technology Sydney focusing on the molecular engineering of antibody fragments and immunotoxins. He was also involved in the characterization of a mAb that induced apoptosis of kappa-myelomas.  This is currently pursued by HaemaLogiX in Phase ...

Close Full biography

Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute

×

Anandi Chowdhury, Ph.D. Candidate, Indian Institute of Technology Delhi

Anandi Chowdhury is a researcher at the Centre of Excellence for Biopharmaceutical Technology, Indian Institute of Technology Delhi, India. With over seven years of experience in biopharmaceutical research, she specializes in protein aggregation, biologic stability, and the development of...

Close Full biography

Anandi Chowdhury, Ph.D. Candidate, Indian Institute of Technology Delhi

×

Michaela Cohrs, PhD student, Ghent University

Michaela Cohrs is a PhD candidate at Ghent University under the supervision of Prof. Hristo Svilenov and Prof. Stefaan De Smedt. Her research focuses on the analysis and prevention of antibody aggregation, with projects ranging from early candidate screening to formulation development and...

Close Full biography

Michaela Cohrs, PhD student, Ghent University

Silvia Crescioli, independent consultant

Mehdi Damaghi, Professor- lab head, Stony Brook Hospital

×

Stefan Dätwyler, Single Use Business Development, ASEPTCONN

Stefan Dätwyler brings over 15 years of experience in commercial growth and leadership, with deep expertise in the single-use market, its dynamics, and its technical requirements.

Close

Stefan Dätwyler, Single Use Business Development, ASEPTCONN

Jeroen de Keijzer, Scientist, Development, Janssen

×

Fabienne DECKERT, Founder and Managing Director, COMPLYOMICS Sàrl

Dr Fabienne Deckert is the founder and Managing Director of Complyomics, a company supporting Life Sciences organizations with customized Quality Systems and tailored Bioanalytical solutions with a focus on compliance with regulatory requirements. With 30 years in the international Pharma industry ...

Close Full biography

Fabienne DECKERT, Founder and Managing Director, COMPLYOMICS Sàrl

Victor Díaz Cortés, Head of Research, OneChain Immunotherapeutics

Susanne Diehl, Global Program Head, Novartis Pharma AG

Harsha Doddihal, Global Clinical Lead, Tellix

Ebenezer Doku, Regulatory Affairs Lead, Roche products Ghana Ltd.

Zorica Dragic, Executive Director Cell Line Screening and Development, Novartis International AG

Nadjia Drici, Global Head of IT Clinical and Development Strategy, Biogen

×

Stefan Dübel, Director, Technical University of Braunschweig

Stefan Dübel is Full Professor of Biotechnology and Director of the corresponding department at the Technical University of Braunschweig, Germany. After completing his PhD at the University of Heidelberg, he joined the German Cancer Research Center (DKFZ) in 1989, where he pioneered in vitro...

Close Full biography

Stefan Dübel, Director, Technical University of Braunschweig

Lasse Ebdrup Pedersen, Associate Professor, Technical University of Denmark

Hilmar EBERSBACH, CSO, Immunos Therapeutics

Nora Eifler, Head Drug Substance Project Management, Novartis

Mourad Farouk Rezk, Independent Global Biotech and Biosimilars Executive, Independent

×

Matthias Feige, , Technical University Munich

Prof. Feige (*1979) pursues an interdisciplinary approach to address fundamental questions in cellular protein biochemistry: how do cells control that the proteins they produce are correctly structured? How is it ensured that defective proteins are recognized and degraded instead of having...

Close Full biography

Matthias Feige, Technical University Munich

×

Nadia Fernandez, Industry Clinical Collaboration Leader, F. Hoffmann-La Roche Ltd.

I have more than 20 years of experience in the pharmaceutical industry and have held various positions in clinical trial management, procurement and medical affairs. As an Industry Clinical Collaboration Leader, I focus on bringing new and innovative treatment combinations to patients through...

Close Full biography

Nadia Fernandez, Industry Clinical Collaboration Leader, F. Hoffmann-La Roche Ltd.

Hector Marcelo Fernandez Lahore, Associate Professor, Luxembourg Institute of Science and Technology

Pierre Ferré, Chief Operating Officer, Compugen Ltd

Dan Foxler, Head of Cell Biology, LabGenius Tx

×

Linnea Franssen, Principal Modelling & Simulation Scientist, Roche

I am a researcher in Translational Modelling & Simulation at Roche. I support large molecule projects through model-based predictions that e.g. support the optimization of compound dosing schedules, predict First-In-Human dosing or select a lead drug candidate. I also develop in silico models...

Close Full biography

Linnea Franssen, Principal Modelling & Simulation Scientist, Roche

×

Tim Fugmann, CSO and Co-founder, Alithea Bio

Tim Fugmann, CSO and Co-Founder of Alithea Biotechnology, holds a PhD from ETH Zurich and was 10 years in biotech industry in Switzerland before being appointed Prof. for mass spectrometry-based proteomics in Giessen, Germany. For many years, he is studying HLA-presented peptides in health and...

Close Full biography

Tim Fugmann, CSO and Co-founder, Alithea Bio

Norbert Furtmann, Head of Computational and High-Throughput Protein Engineering, Sanofi

×

Sreekanth Gattu, Global Program Head, Sandoz

Global Program Head at Sandoz Biopharmaceuticals, Basel, Switzerland; overseeing end to end development of biosimilars starting from early R&D, clinical development through commercialization. A physician by training and has about 15 years of experience in clinical development covering...

Close Full biography

Sreekanth Gattu, Global Program Head, Sandoz

Krist Gernaey, Professor, Chemical & Biochemical Engineering, Technical University of Denmark

Felix Geyer, PhD student, TU Darmstadt

Virginia Ghizzani, PhD, University of Pavia

×

Ettore Gilardoni, Head of Mass Spectrometry, Philochem

Ettore Gilardoni is Head of Mass Spectrometry at Philochem AG. The team main activities vary from biodistribution of small organic molecules in biospecimens; biopharmaceuticals characterization, and proteomics application for target identification; host cell proteins characterization, and mechanism ...

Close Full biography

Ettore Gilardoni, Head of Mass Spectrometry, Philochem

Arnaud Goepfert, Director Protein Sciences, Bright Peak Therapeutics

×

Steffen Goletz, Professor, Department of Biotechnology and Biomedicine, Danish Technical University

PhD, Professor, Head of RG Biotherapeutic Glycoengineering & Immunology, DTU Bioengineering, Technical University of Denmark. Focus on novel bi- and multispecific antibody and cell-based therapeutics in immunooncology and infectious diseases. After early career in academic research, e.g. MDC in ...

Close Full biography

Steffen Goletz, Professor, Department of Biotechnology and Biomedicine, Danish Technical University

×

A. Pedro Gonçalves, Principal scientist, VTT Technical Research Centre of Finland

I am a fungal biologist and, more formally, a Principal Scientist in the Industrial Biotechnology and Food research division at VTT - Technical Research Centre of Finland. Our Protein Production team excels in fungal strain engineering and high-yield production of enzymes as well as...

Close Full biography

A. Pedro Gonçalves, Principal scientist, VTT Technical Research Centre of Finland

Francisca Gouveia, Innovation, Data and Digital & Validation Lead, Novartis

×

Torbjorn Graslund, prof., KTH Royal Institute of Technology

Professor Torbjörn Gräslund holds a Ph.D. in Biotechnology from KTH - Royal Institute of Technology, Sweden, since 2001. Following two years of post-doctoral training with Professor Carlos Barbas at the Scripps Research Institute, he has been a principal investigator at the Department of Protein...

Close Full biography

Torbjorn Graslund, prof., KTH Royal Institute of Technology

×

Ivan Gudelj, Assistant Professor, University of Zagreb, Faculty of Pharmacy and Biochemistry

Ivan Gudelj is an Assistant Professor at the University of Zagreb, Faculty of Pharmacy and Biochemistry, specializing in glycoscience and antibody biology. His research focuses on IgG glycosylation and its role in immune regulation and disease. He has authored over 40 peer-reviewed publications and ...

Close Full biography

Ivan Gudelj, Assistant Professor, University of Zagreb, Faculty of Pharmacy and Biochemistry

×

Anissa Harbi, Immunologist, Les Hôpitaux d'Alger

Anissa Harbi is an Immunologist MD from Annaba, Algeria, with a strong background in clinical research and patient care. Currently serving as an Immunologist at Les Hôpitaux d'Alger, Anissa is dedicated to advancing medical knowledge and improving patient outcomes.

Close

Anissa Harbi, Immunologist, Les Hôpitaux d'Alger

×

Julia Harwardt, Scientist, Merck Healthcare KGaA

Julia Harwardt is a Bench Scientist in the Antibody Discovery & Protein Engineering department at Merck KGaA. She joined the company after completing her PhD in the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. With a strong background in biochemistry and antibody...

Close Full biography

Julia Harwardt, Scientist, Merck Healthcare KGaA

×

Hooman Hefzi, Associate Professor, Danish Technical University

Hooman is currently an Associate Professor at the Technical University of Denmark where his research group broadly aims to engineer mammalian cells for improved cellular behavior in fields including biologics manufacturing and cultivated meat. He previously led the Omics and Modeling Team in...

Close Full biography

Hooman Hefzi, Associate Professor, Danish Technical University

×

Oliver Hill, Senior Director Protein Engineering, Yumab GmbH

Oliver Hill is an experienced biotechnology professional specializing in protein engineering and drug discovery. Currently, he serves as Senior Director of Protein Engineering at YUMAB GmbH, focusing on advancing antibody-based therapeutics for clients. Oliver has held leadership roles at TriCos...

Close Full biography

Oliver Hill, Senior Director Protein Engineering, Yumab GmbH

×

Sebastian Hörner, Senior Scientist, BiconY Therapeutics

Sebastian Hörner joined BiconY Therapeutics as a Senior Scientist in 2023. He studied technical biology at the University of Stuttgart from 2011 to 2017, where he started his work in the field of recombinant antibodies in the lab of Roland Kontermann. From 2017 to 2021, he worked as a PhD candidate ...

Close Full biography

Sebastian Hörner, Senior Scientist, BiconY Therapeutics

Michael Huebner, Director, Country Lead EIP, Johnson & Johnson Innovation

×

Martin Huelsmeyer, Senior Principal Research Scientist, AbbVie

Martin Huelsmeyer is chemist by training and received his PhD in Structural Biology from Technical University Braunschweig, Germany. Prior joining Abbvie in 2012, he held positions in academia at University of Würzburg, Technical University Berlin, University Hospital Charité Berlin and was...

Close Full biography

Martin Huelsmeyer, Senior Principal Research Scientist, AbbVie

×

Melita Irving, Group Leader, University of lausanne

Originally from Canada, Dr. Melita Irving began working in the field of T-cell engineering for cancer immunotherapy in Switzerland in 2007. She has been a group leader at the Ludwig Institute for Cancer Research in the Department of Oncology at the University of Lausanne for the past 12...

Close Full biography

Melita Irving, Group Leader, University of lausanne

Barbara Jackova, Post-doctoral researcher in Biotechnology, Sanofi

Ruediger Jankowsky, CEO, AATec Medical GmbH

×

Colette Johnston, VP - Head of Product Platform Research, Enara Bio

Colette has been Head of Product Pipeline at EnaraBio since 2023, building bispecific T cell engagers that recognise novel cancer targets. She has more than 15 years experience in the biopharmaceutical industry, with a strong focus on antibody discovery, transgenic platforms, protein engineering...

Close Full biography

Colette Johnston, VP - Head of Product Platform Research, Enara Bio

×

Peter Jorgensen, Chief Executive Officer, Danish Generic and Biosimilar Medicines Industry Association (IGL)

Master in Political Science from the University of Copenhagen45+ years of professional experience, including:Head of section in the Ministries of Social Affairs and of LabourLabour Counsellor at the Danish UN-mission in GenevaHealth Counsellor at the Danish EU-representation in BrusselsSpokesman in ...

Close Full biography

Peter Jorgensen, Chief Executive Officer, Danish Generic and Biosimilar Medicines Industry Association (IGL)

×

Alois Jungbauer, Professor, B.O.K.U.

Alois Jungbauer holds a doctorate in food technology and biotechnology from BOKU. He is retired Professor Emeritus of Downstream Processing at the Institute of Bioprocess Science and Technology at BOKU University, Adjunct Professor at University of Adelaide and an active scientist at the Austrian...

Close Full biography

Alois Jungbauer, Professor, B.O.K.U.

×

Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London

Translational B cell and cancer immunologist with academic and biotechnology experience in the UK and USA. She heads a cancer antibody discovery team focusing on dissecting the crosstalk between human immunity and solid tumours and understanding the impact of antibody isotype on therapeutic...

Close Full biography

Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London

Thomas Klünemann, Director of New Technologies and Antibody Engineering, Yumab GmbH

×

Harald Kolmar, Head of Department Applied Biochemistry, TU Darmstadt Biochemie

Harald Kolmar is full professor at the TechnicalUniversität Darmstadt, Germany where he heads since 2005 the Department of Applied Biochemistry. He holds a Ph.D. and habilitation in biochemistry and molecular biology. His current scientific interests mainly focus on protein engineering and...

Close Full biography

Harald Kolmar, Head of Department Applied Biochemistry, TU Darmstadt Biochemie

Kasia Kozakowska-McDonnell, Associate Director, Analytical CMC Lead, AstraZeneca

×

Carsten Krantz, Associate Director, Novartis

Carsten Krantz, PhD, is a highly accomplished bioanalytical scientist with broad expertise across a spectrum of advanced methodologies, including LC-MS/MS, ligand binding assays, ELISA, MSD, and neutralizing antibody assays. Currently serving as an Associate Director at Novartis, he leads a global...

Close Full biography

Carsten Krantz, Associate Director, Novartis

×

Emanuel Kreidl, Senior Expert, Principal Scientist, Novartis

Emanuel Kreidl is a seasoned Senior Expert and Principal Scientist at Novartis, with a strong background in biologics research and development. With over 15 years of experience in the pharmaceutical industry, Emanuel has made significant contributions to the field of biologics, particularly in the...

Close Full biography

Emanuel Kreidl, Senior Expert, Principal Scientist, Novartis

×

Bernd Liedert, Founder / Consultant, BL Consulting

ernd is a border-crosser between the worlds of regulatory and clinical development of biopharmaceutical compounds. A seasoned executive with demonstrated experience of 25+ years’ working in academia (West German Cancer Center, University of Essen Medical School), in regulatory agencies (PEI, EMA)...

Close Full biography

Bernd Liedert, Founder / Consultant, BL Consulting

×

Alfred Lim, Director of Lab Research, Etcembly Ltd

Alfred is Director of Lab Research at Etcembly, where he leads the development of new TCR drug candidates from discovery through to preclinical characterization and translational development. He was previously Head of Discovery at Theolytics and was responsible for candidate optimisation and lead...

Close Full biography

Alfred Lim, Director of Lab Research, Etcembly Ltd

×

Britta Lipinski, PhD Student, Merck Healthcare KGaA

Britta Lipinski is a PhD candidate in the Antibody Discovery and Protein Engineering Department of Merck KGaA, supervised by Stefan Zielonka, where she works in close collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research focuses on the...

Close Full biography

Britta Lipinski, PhD Student, Merck Healthcare KGaA

Lara Lorthiois, Formerly: Director, Customer strategic initiatives, RLT, Independent

×

Robin Löving, CSO, Salipro Biotech AB

Robin Löving, Chief Scientific Officer (CSO) at Salipro Biotech. Robin has more than 15 years’ experience working with therapeutically interesting membrane proteins. He did his PhD with a focus on membrane proteins and antigen design at the Karolinska Institute in Stockholm, Sweden. After being...

Close Full biography

Robin Löving, CSO, Salipro Biotech AB

Declan Lowney, Director of Stability Sciences, BioTherapeutics Development Analytical Development, Johnson & Johnson Innovation

×

Heinz Lubenau, Chief Executive Officer, NEC Bio

Heinz Lubenau is currently Chief Executive Officer and co-founder of NEC Bio Therapeutics where he is leading the AI-empowered personalized neoantigen drug development which includes the proprietary product NECVAX-NEO1 and the clinical collaboration with Transgene’s MyVac product. He has been...

Close Full biography

Heinz Lubenau, Chief Executive Officer, NEC Bio

Francesca Luciani, Senior Researcher, Instituto Superiore di Sanita

×

Bernard Maillere, Head of laboratory, CEA

Bernard Maillere is head of the Laboratory of Cellular Immunology and Biotechnology of the CEA, a French governmental research institute. He  is also head of the immunology section of the doctoral school "therapeutic innovation" of the University of Paris-Saclay. He holds a Master's...

Close Full biography

Bernard Maillere, Head of laboratory, CEA

Dr Alessio Maiolica, Director, Novartis

×

Nirmal Mallick, Student, IIT Delhi

I, Nirmal Mallick, is currently pursuing research at Indian Institute of Technology, Delhi in the area of Bioreactor Design and process optimization under the guidance of Prof. Anurag S. Rathore. During this research I worked with the geometry of different size of reactor starting from 0.6 ltr to...

Close Full biography

Nirmal Mallick, Student, IIT Delhi

×

Salah Mansour, Associate Professor, iNKT Cell Therapy, Salah Mansour - University of Southampton

Dr Salah Mansour is an Associate Professor at the University of Southampton. His research focuses on unconventional T cells, particularly CD1-restricted and invariant natural killer T (iNKT) cells, and their application in cancer immunotherapy and infectious disease. His work combines structural...

Close Full biography

Salah Mansour, Associate Professor, iNKT Cell Therapy, Salah Mansour - University of Southampton

×

Julie Maréchal-Jamil, Senior Director Pharmaceutical Policy, Medicines for Europe

Julie Maréchal-Jamil is a seasoned professional with over 15 years of experience in the pharmaceutical industry. Currently serving as the Senior Director of Pharmaceutical Policy at Medicines for Europe, she is a respected expert in the field of biologics and healthcare policy. Julie's...

Close Full biography

Julie Maréchal-Jamil, Senior Director Pharmaceutical Policy, Medicines for Europe

×

Umberto Maria Battisti, Associate Professor, University of Copenhagen

Dr. Umberto Maria Battisti is a medicinal and radiochemist with over 10 years of experience. From 2018 to 2026, he served as Assistant and then Associate Professor in the Department of Medicinal Chemistry at the University of Copenhagen, focusing on bioorthogonal chemistry for in vivo PET imaging...

Close Full biography

Umberto Maria Battisti, Associate Professor, University of Copenhagen

Johanna Marines, Head of Preclinical, Mabqi

Wyatt McDonnell, CEO, Infinimmune

×

Duccio Medini, Chief Technology and Science Officer, Pitt BioForge

Duccio Medini is a scientist and pharmaceutical executive currently serving as Chief Science and Technology Officer at Pitt BioForge (Pittsburgh, PA) and as Strategic Data Science Director at Toscana Life Sciences Foundation (Siena, Italy)He designed and led the Wellcome Leap $60M "R3: RNA...

Close Full biography

Duccio Medini, Chief Technology and Science Officer, Pitt BioForge

Paula Meleady, Associate Professor, Dublin City University

Nicolas Melin, CEO of AquiLiv, AquiLiv

×

Virginia Metrangolo, Postdoc/Co-founder CSO PanTarg, University of Copenhagen

Virginia Metrangolo is a Medical biotechnologist working as a postdoctoral researcher in the Engelholm research group at the Finsen Laboratory/Biotech Research and Innovation Centre in Copenhagen. Her research work involves the development of antibody-based therapies, mostly antibody-drug...

Close Full biography

Virginia Metrangolo, Postdoc/Co-founder CSO PanTarg, University of Copenhagen

Lydia Michaut, Director scientific governance PK sciences, Novartis

×

Enkelejda Miho, Professor Of Digital Life Science Sciences, University of Applied Sciences Northwestern Switzerland

Enkelejda Miho is Professor of Digital Life Sciences at the FHNW University of Applied Sciences and Arts Northwestern Switzerland. She is head of the Laboratory of Artificial Intelligence in Health (www.aihealth.ch). Her research is focused in the application of artificial intelligence to health...

Close Full biography

Enkelejda Miho, Professor Of Digital Life Science Sciences, University of Applied Sciences Northwestern Switzerland

×

Anika Mijakovac, Expert associate/Senior researcher, Faculty of Science, University of Zagreb

Dr. Anika Mijakovac is an expert associate at the Faculty of Science, University of Zagreb and a senior researcher in Genos working in the field of epigenetics and protein glycobiology. Her primary focus is immunoglobulin G (IgG) glycosylation in aging and disease. In her research she uses...

Close Full biography

Anika Mijakovac, Expert associate/Senior researcher, Faculty of Science, University of Zagreb

×

DR Michel Mikhail, Expert in Global Regulatory Affairs and Governmental relations, Expert in Biosimilars, Independent

Dr. Michel Mikhail has more than 30 years Pharmaceutical Industry experience and track record of achievement in R & D and International Regulatory Affairs in large multinational Research-based pharmaceutical Companies as well as Generic & Biosimilars companies. He also has global experience ...

Close Full biography

DR Michel Mikhail, Expert in Global Regulatory Affairs and Governmental relations, Expert in Biosimilars, Independent

Élodie Miranda, SVP General Manager International Markets, Iovance Biotherapeutics

Maria Mitsi, Senior Scientist, University Hospital Zurich

×

Ravishankara MN, Senior General Manager, Analytics- Function Head, Sun Pharma

Ravishankara MN currently hold the position of Senior General Manager at Sun Pharmaceutical Industries Limited and leading Team involved in Analytical activities related to development of Biologics and Peptides. He is having about 23 years of experience and his research interest includes Critical...

Close Full biography

Ravishankara MN, Senior General Manager, Analytics- Function Head, Sun Pharma

×

Lorenzo Montrasio, Secretary General, VolRethics

Since 2024, Lorenzo has worked as an independent advisor, collaborating with national governments and international organizations to promote partnerships for medicine development and strengthen regulatory systems. Previously, he led the work on access to innovative treatments and technologies at...

Close Full biography

Lorenzo Montrasio, Secretary General, VolRethics

×

Ejvind Mørtz, Chief Scientific Officer and Co-Founder, Alphalyse

Ejvind Mørtz is a leading figure in proteomics and mass spectrometry analysis with more than 30 years of experience in biotechnology and protein biologics development. He holds a PhD in Protein Chemistry and Molecular Biology from the University of Southern Denmark. He has specialized in developing ...

Close Full biography

Ejvind Mørtz, Chief Scientific Officer and Co-Founder, Alphalyse

×

Guillaume Mottet, Lab Head, SANOFI

After completing his Ph.D. studies in 2009 in microfluidic chip field, he continued as postdoctoral fellow at Institut Curie in the team of Jean Louis Viovy and developed thermoplastic chips for diagnostics. In 2013, he went on to apply droplet microfluidics for the study of molecular evolution in...

Close Full biography

Guillaume Mottet, Lab Head, SANOFI

Michael Muenzberg, CEO, Targeted Soloutions

Christian Neusüß, Professor Analytical Chemistry, Hochschule Aalen

Sarfaraz Niazi, CEO, Karyo Biologics, LLC

×

Björn Niebel, Senior Principal Scientist, Sanofi Ghent - Sanofi R&D

Björn Niebel is a Senior Principal Scientist, Group Head in the Discovery Department of the Nanobody Research Platform at Sanofi Ghent. Björn received his master’s degree in Chemistry from the University of Braunschweig, Germany in 2006 and holds a PhD in Biochemistry from the University of...

Close Full biography

Björn Niebel, Senior Principal Scientist, Sanofi Ghent - Sanofi R&D

David Öling, Director - Molecular Biology and Recombinant Protein Production, AstraZeneca

Ayman Oweida, Associate Professor, Canada Research Chair, Université de Sherbrooke

Vijaya Pattabiraman, Co-founder & CTO, Bright Peak Therapeutics

×

Matthias Peipp, Head - Division of Antibody-Based Immunotherapy, UKSH - University Hospital Schleswig-Holstein

Matthias received his PhD at the chair of genetics at the Friedrich-Alexander-University (Erlangen- Nuremberg, Germany). In 2015 he was awarded an endowed professorship, the “Mildred-Scheel-Professorship for Experimental Antibody-Based Cancer Immunotherapy”. Matthias has a long-standing expertise...

Close Full biography

Matthias Peipp, Head - Division of Antibody-Based Immunotherapy, UKSH - University Hospital Schleswig-Holstein

×

Kalyani Pemmaraju, Director - Operations (Formulation, Fill/Finish and Packaging), External Supply and Manufacturing, AstraZeneca

Kalyani is a biopharmaceutical professional with 30 years of experience in various aspects of biologics, such as CMC development, CMC regulatory, large-scale manufacturing, launch and commercialization.  She worked across multiple therapeutic areas...

Close Full biography

Kalyani Pemmaraju, Director - Operations (Formulation, Fill/Finish and Packaging), External Supply and Manufacturing, AstraZeneca

×

Rob Pengelly, Senior Scientist, Etcembly Ltd

Rob is currently Senior Scientist at Etcembly, where he leads the protein engineering pipeline in biologics development. After completing his PhD in structural biology at the University of St Andrews, Rob spent six years studying TCR-ligand interactions using various biochemical assays coupled with ...

Close Full biography

Rob Pengelly, Senior Scientist, Etcembly Ltd

×

Isabelle Petit-Topin, Team/Lab Lead in Downstream Process _ Manufacturing Science and Technology (DSP MS and T), Novartis France

Isabelle Petit Topin is a passionate professional for Protein biochemistry and all that has to do with protein in general. Graduated at the University Paris Diderot, Isabelle obtained her PhD in 2009 (CIFRE HRA Pharma - Inserm - Paris) in Protein Biochemistry and Crystallography. After her...

Close Full biography

Isabelle Petit-Topin, Team/Lab Lead in Downstream Process _ Manufacturing Science and Technology (DSP MS and T), Novartis France

Maria Pihlgren Bosch, Senior Director, Ichnos Glenmark Innovation, IGI

Sebastian Pirner, Scientist, Roche

×

Andreas Plueckthun, Professor, University of Zurich

Andreas Plueckthun is a distinguished Professor of Biochemistry and the Director of the Department of Biochemistry at the University of Zurich. With a strong background in protein engineering and molecular biology, he is a renowned expert in the field of biologics. Dr. Plueckthun's research...

Close Full biography

Andreas Plueckthun, Professor, University of Zurich

Carolina Pola, CEO, Stab Therapeutics

×

Philipp Probst, Director ADC Research, Araris Biotech AG

Philipp Probst is Director of ADC Research at Araris Biotech AG, a Swiss biotech company located in Au ZH pioneering a novel linker technology for antibody-drug conjugates. He studied Pharmaceutical Sciences and received his PhD from ETH Zürich in 2018, where he worked in the group of Prof. Dario...

Close Full biography

Philipp Probst, Director ADC Research, Araris Biotech AG

×

Emanuele Puca, Chief Operating Officer, Philochem

Chief Operating Officer of the Philogen Group and Board Member of Philochem AG (Philogen discovery center). Graduated in Medicinal Chemistry at La Sapienza University and performed Ph.D. studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of...

Close Full biography

Emanuele Puca, Chief Operating Officer, Philochem

Narasimha Pullaguri, Scientist, Hetero Biopharma Limited

Steven Quayle, Senior Vice President & Head of Research and Translational Medicine, Cue Biopharma

×

Moutih Rafei, Full Professor, University of Montreal

Dr. Rafei is an immunologist by training focused on the development of therapies within the immuno-oncology space. Throughout the past decade, he accumulated profound knowledge and insight in the fields of T-cell development, stem cell biology, cancer immunotherapy and autoimmune diseases. While...

Close Full biography

Moutih Rafei, Full Professor, University of Montreal

Monica Raimo, Director of Product and Process Development, Glycostem Therapeutics

×

Tobias Rainer, Senior Associate Scientist, Roche Diagnostics GmbH

Tobias is a mass spectrometrist at Roche Pharma Development in Germany. Coming from the Italian alps, he studied chemistry in Austria and Scotland. Among other responsibilities, his work focuses on advancing the in-depth characterization of novel biopharmaceuticals. Being a passionate...

Close Full biography

Tobias Rainer, Senior Associate Scientist, Roche Diagnostics GmbH

Farshad Ramazani, Functional lead, Novartis

×

Alexander Rau, Senior Scientist Protein Engineering, Anaveon

Alexander joined Anaveon in 2022 as a protein engineer, focused on developing the next generation of antibody-cytokine fusion proteins for cancer therapy. He previously worked at a biotech company, focusing on the generation of antibody therapeutics for immuno-oncology. He also has a strong...

Close Full biography

Alexander Rau, Senior Scientist Protein Engineering, Anaveon

×

Sudarshan Reddy, CEO, Oncosimis Biotech Pvt Ltd

Dr. Reddy is the Founder & CEO of Oncosimis Biotech Pvt. Ltd., and an accomplished leader in drug discovery and innovation in the fields of metabolic and neuromuscular diseases. Under Dr. Reddy’s leadership, Oncosimis Biotech has achieved several notable milestones, including securing 30...

Close Full biography

Sudarshan Reddy, CEO, Oncosimis Biotech Pvt Ltd

Isabell Remus, Global Head of Biosimilars, Sandoz

Alexandra Richardson, Executive Director, Institut Clayton de Recherche

×

Valéry Risson, Director Value and Access, Novartis

Valéry Risson is a seasoned professional in the biopharmaceutical industry, currently serving as the Director of RLT Value & Access International at Novartis. With a strong background in market access and pricing strategies, Valéry brings a wealth of experience to the table. Throughout her...

Close Full biography

Valéry Risson, Director Value and Access, Novartis

×

Johan Rockberg, Professor, KTH

Professor in directed evolution and antibody technology at KTH Royal Inst.Technology, Sweden. Director of GeneNova, a center focused on developing platforms for more cost effective, safe and efficacious AAV-based gene therapy through interdisciplinary industry and academia collaborations. He is an...

Close Full biography

Johan Rockberg, Professor, KTH

×

Ali Roghanian, Associate Prof in Cancer Immunotherapy, University of Southampton

Ali Roghanian is an Associate Professor in Cancer Immunotherapy at the University of Southampton, UK. His work bridges basic and translational immunology with a strong focus on developing next‑generation biologics for cancer treatment. Ali’s research centres on understanding how immune pathways can ...

Close Full biography

Ali Roghanian, Associate Prof in Cancer Immunotherapy, University of Southampton

×

Alexis Rossignol, Project Manager in analytical development and validation, Clean Cells – Naobios

Alexis Rossignol earned his PhD in 2007 on the theme of anti-tumor immunology from the University of Poitiers (France). He completed his post-doctoral research in a lab dedicated to monoclonal antibodies pharmacogenomics in Tours (France), where he developed in vitro cell-based assays to explore...

Close Full biography

Alexis Rossignol, Project Manager in analytical development and validation, Clean Cells – Naobios

×

Christine Rothe, Chief Development Officer, iOmx Therapeutics AG

Christine Rothe serves as Chief Development Officer at iOmx Therapeutics where she is responsible for research and development programs. Christine has a long-standing track record in discovery and development of drug candidates. Before joining iOmx, Christine held positions of increasing...

Close Full biography

Christine Rothe, Chief Development Officer, iOmx Therapeutics AG

Viacheslav Rusanov, Post-doc researcher, Sanofi

Rahul Saikia, Head of M&A, Rising Pharmaceuticals

Stefano Sammicheli, Senior Director, Ichnos Glenmark Innovation

×

Carina Schey, CEO, Shout

Carina Schey has many years of both pharmaceutical industry and clinical pharmacy experience. With a doctorate awarded by the University of Groningen, Carina’s experience span across the healthcare ecosystem, clinical development, health technology assessment, and reimbursement strategy. After...

Close Full biography

Carina Schey, CEO, Shout

×

Jan Schnitzer, Director, P.R.I.S.M.

PRISM was founded in 2009 by Dr. Schnitzer, a world-renowned expert in vascular biology with almost four decades of research experience.  Upon earning his MD in 1985 from the University of Pittsburgh, he served as a Post-Doctoral Fellow in the Department of Cell Biology, Yale University Medical...

Close Full biography

Jan Schnitzer, Director, P.R.I.S.M.

Andreas Seidl, CSO, Formycon AG

×

Oliver Seifert, Post-Doc, University of Stuttgart

Oliver Seifert is a senior scientist in the laboratory of Roland Kontermann at the University of Stuttgart and leads the bispecific antibody group. He is an expert in the field of antibody engineering with more than 20 years experience. His scientific research covers development and...

Close Full biography

Oliver Seifert, Post-Doc, University of Stuttgart

Aridni Shah, Co-Founder and Chief Executive Officer, immunitoAI Private Limited

Daya Shankar, Founder & Chief AI Officer, VaidyaAI, Dean School of Sciences & AI Faculty, Woxsen University, Woxsen University

Alexander Sherman, Director, Center for Innovation and Bioinformatics, Mass General Hospital, Harvard Medical School

×

Arne Skerra, Professor, TU Munich

Dr. Arne Skerra is Full Professor at the Technical University of Munich in the School of Life Sciences. He started his scientific career in the field of protein engineering, where he pioneered the biosynthesis of functional antibody fragments in E. coli. Apart from several other contributions to...

Close Full biography

Arne Skerra, Professor, TU Munich

×

Jae Sly, Ceo, Pathways Preclinical Partners

Dr. Sly has over 25 years of experience in biomanuacturing, spanning across R&D to clinical production. Dr. Sly has established a wide network of collaborators in the bioprocessing Industry, including patent-holding biopharmaceutical companies, contract research organizations (CROs), and...

Close Full biography

Jae Sly, Ceo, Pathways Preclinical Partners

Elizaveta Solovyeva, Senior Expert Data Scientist, Novartis

Benjamin Sommer, Associate Director USP Development, Novartis

Andreas Stengl, Team Lead, Protein Engineering, Ludwig Maximilians University Munich

Lorenz Tanner, Member of Patient Board, SAKK Swiss Group for Clinical Cancer Research

Nazanin Tatari, Post-Doctoral Fellow, University Hospital Basel

×

Anike Te, Chief Strategy Officer; Aegis Professor of Engineering Biology, Lucideon & University of Bristol

Anike Te is an industrial strategist, honorary professor and advisor focused on strategic growth and innovation. Anike was appointed as Chief Strategy Officer of Lucideon in 2018, where she previously served on Lucideon’s Group Business Development Board and is currently a member of the Strategy...

Close Full biography

Anike Te, Chief Strategy Officer; Aegis Professor of Engineering Biology, Lucideon & University of Bristol

×

Bert Thomas, Senior Vice President Of Business Development, Bio-Thera Solutions

Bert is currently Senior Vice President, Business Development of Bio-Thera Solutions, a China-based pharmaceutical company, joining the company in 2017. Prior to joining Bio-Thera Solutions, Bert was the CEO of the Sarcoma Foundation of America (SFA), a rare cancer patient advocacy...

Close Full biography

Bert Thomas, Senior Vice President Of Business Development, Bio-Thera Solutions

×

Jakub Tomala, Assistant Research Professor, John Hopkins University

Dr. Jakub Tomala earned his Master Science degree and Ph.D., both in Immunology, at Charles University in Prague, Czech Republic. After completing a postdoctoral fellowship at Johns Hopkins University, School of Medicine, in 2018, Dr. Tomala became senior researcher in the Laboratory of...

Close Full biography

Jakub Tomala, Assistant Research Professor, John Hopkins University

×

Darren Tomlinson, Professor, University of Leeds

Professor Darren Tomlinson is Head of the School of Molecular and Cellular Biology at the University of Leeds and co-inventor of the Adhiron protein scaffold, a versatile engineered binding platform widely used in research and diagnostics. His work focuses on protein engineering approaches that...

Close Full biography

Darren Tomlinson, Professor, University of Leeds

Thi Hong Hue Tran, PhD candidate - Antibody Discovery & Protein Engineering, Merck Healthcare KGaA

×

Marco Traub, Chief Executive Officer, TESCT - The Trans European Stem Cell Therapy Society

Dr. Marco Traub has gained considerable experience in several research, management, and educational projects over the past 25 years. He is the founder of the Trans European Stem Cell Therapy Consortium (TESCT) and acts since 2005 as Chair of the TESCT consortium and as EU-Commission Expert...

Close Full biography

Marco Traub, Chief Executive Officer, TESCT - The Trans European Stem Cell Therapy Society

×

Laura Unmuth, Bench Scientist & PhD candidate - Antibody Discovery & Protein Engineering, Merck KGaA

Laura Unmuth is a Bench Scientist and PhD candidate in the Antibody Discovery & Protein Engineering department of Merck KGaA, supervised by Stefan Zielonka and in collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research work focuses on the...

Close Full biography

Laura Unmuth, Bench Scientist & PhD candidate - Antibody Discovery & Protein Engineering, Merck KGaA

×

Stefanie Urlinger, CSO, Cimeio Therapeutics

Stefanie Urlinger is Chief Scientific Officer at Cimeio Therapeutics, a biotech company developing state-of-the-art immunotherapies, along with paired, engineered hematopoietic stem cells. Stefanie has over 20 years of expertise in large molecule engineering and early development and has led...

Close Full biography

Stefanie Urlinger, CSO, Cimeio Therapeutics

×

Thomas Valerius, Assistant Professor, Section For Stem Cell Transplantation And Immunotherapy, University of Kiel

Thomas Valerius studied medicine at the University of Erlangen-Nürnberg, Germany. After his training in internal medicine, he specialized in Hematology/Oncology and Rheumatology. Since May 2003, he has been working at the University in Kiel, Germany, where he currently is assistant professor at the ...

Close Full biography

Thomas Valerius, Assistant Professor, Section For Stem Cell Transplantation And Immunotherapy, University of Kiel

×

Erik van den Berg, CEO, Memo-Therapeutics AG

Erik van den Berg is the CEO of Memo Therapeutics AG, bringing over 25 years of industry experience and a proven track record in leadership and company growth. He is the former CEO of AM-Pharma and holds chairmanships in Step Pharma and TargED Therapeutics and was the co-founder and (executive)...

Close Full biography

Erik van den Berg, CEO, Memo-Therapeutics AG

×

Annette Vogl, VP, Biology and Translational Research, Tubulis GmbH

2015-2020: Scientist at Genentech,Since 2020: Head of Biology / VP, Biology and Translational Research at TubulisScientific training background: molecular cell biology, protein degradation, cellular protein homeostasis

Close

Annette Vogl, VP, Biology and Translational Research, Tubulis GmbH

×

Johannes vom Berg, PI/CSO, University of Zurich

Johannes vom Berg is a group leader at the Institute of Laboratory Animal Science (LTK), University of Zurich, Switzerland since 2019. Before that his main occupation was to direct the LTK transgenic mouse core facility of the University of Zurich from 2014-2018. He studied biology and molecular...

Close Full biography

Johannes vom Berg, PI/CSO, University of Zurich

Yannik Weber, AbbVie

×

Ronnie Wei, Head of Biologics Discovery and Development, ModeX Therapeutics

Ronnie R. Wei, PhD, MBA is a biopharmaceutical executive with nearly 20 years of experience in biologics discovery and early-stage drug development, specializing in oncology, immune-oncology, and infectious diseases. She currently leads Biologics Discovery and Development at ModeX...

Close Full biography

Ronnie Wei, Head of Biologics Discovery and Development, ModeX Therapeutics

×

Leon Willis, Postdoctoral Fellow, University of Leeds

Dr Leon F Willis MRSC is postdoctoral research fellow at the Astbury Centre for Structural Molecular Biology, University of Leeds. He is currently researcher co-investigator on an EPSRC-funded grant, supervised by Prof David Brockwell, Prof Sheena Radford OBE FRS FMedSci and Prof Nik Kapur, as well ...

Close Full biography

Leon Willis, Postdoctoral Fellow, University of Leeds

×

Jörg Wischhusen, Professor, Universitätsklinikum Würzburg

Jörg Wischhusen studied biochemistry in Tübingen, Germany. During his thesis on mechanisms of immune escape in glioma (mentored by Michael Weller and Hans-Georg Rammensee) he performed early work in the field of experimental immune checkpoint blockade. In 2005 he was recruited as a junior research...

Close Full biography

Jörg Wischhusen, Professor, Universitätsklinikum Würzburg

Armin Wolf, Strategic Tox Consultant, awoCON

×

Michael Zaiac, Head of Medical Affairs Oncology Europe and Canada, Daiichi Sankyo

My passion are science and people. Hence,  it appealed to me to study medicine and following undergraduate studies in Berlin, I went into surgery in the UK and Germany,  and eventually I found my passion in surgical oncology, caring for patients with breast cancer, sarcoma, melanoma and many other...

Close Full biography

Michael Zaiac, Head of Medical Affairs Oncology Europe and Canada, Daiichi Sankyo